ATOS saw its Momentum Indicator move above the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 74 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
The Moving Average Convergence Divergence (MACD) for ATOS just turned positive on October 02, 2026. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
ATOS moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATOS crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +16.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in 180 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ATOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for ATOS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 52 cases where ATOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ATOS entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.945) is normal, around the industry mean (3.009). P/E Ratio (-0.585) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ATOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FBLG saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator turned negative. In 47 of the 48 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
FBLG moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FBLG crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBLG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FBLG entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBLG advanced for three days, in 101 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
FBLG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.380) is normal, around the industry mean (3.009). P/E Ratio (-0.180) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FBLG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBLG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ATOS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | |
P/E GROWTH RATING 1..100 | 40 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ATOS | FBLG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 85% | N/A |
| Momentum ODDS (%) | 1 day ago 82% | 6 days ago 90% |
| MACD ODDS (%) | 1 day ago 74% | N/A |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| Advances ODDS (%) | 7 days ago 78% | 26 days ago 81% |
| Declines ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATOS’s FA Score shows that 0 FA rating(s) are green while FBLG’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATOS’s TA Score shows that 6 TA indicator(s) are bullish while FBLG’s TA Score has 3 bullish TA indicator(s).
ATOS (@Biotechnology) experienced а -0.78% price change this week, while FBLG (@Biotechnology) price change was -4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
ATOS is expected to report earnings on Nov 11, 2026.
FBLG is expected to report earnings on Oct 30, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ATOS | 1D Price Change % | ||
|---|---|---|---|---|
| ATOS | 100% | -0.78% | ||
| AXON - ATOS | 42% Loosely correlated | +2.49% | ||
| AKBA - ATOS | 36% Loosely correlated | -9.12% | ||
| RARE - ATOS | 35% Loosely correlated | +6.30% | ||
| RCKT - ATOS | 34% Loosely correlated | +4.46% | ||
| ARRY - ATOS | 34% Loosely correlated | +2.15% | ||
More | ||||
A.I.dvisor indicates that over the last year, FBLG has been loosely correlated with PEPG. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if FBLG jumps, then PEPG could also see price increases.
| Ticker / NAME | Correlation To FBLG | 1D Price Change % | ||
|---|---|---|---|---|
| FBLG | 100% | -2.56% | ||
| PEPG - FBLG | 37% Loosely correlated | +6.30% | ||
| ATOS - FBLG | 29% Poorly correlated | -0.78% | ||
| ZNTL - FBLG | 28% Poorly correlated | +3.91% | ||
| CELC - FBLG | 28% Poorly correlated | +5.04% | ||
| TBPH - FBLG | 27% Poorly correlated | N/A | ||
More | ||||